Literature DB >> 12610125

Genetic fate of recombinant adeno-associated virus vector genomes in muscle.

Bruce C Schnepp1, K Reed Clark, Dori L Klemanski, Christina A Pacak, Philip R Johnson.   

Abstract

Recombinant adeno-associated virus (rAAV) vectors are promising human gene transfer vectors, because they mediate long-term gene expression in vivo. The vector DNA form responsible for sustained gene expression has not been clearly defined, but it has been presumed that the vector integrates to some degree and persists in this manner. Using two independent methods, we were unable to identify rAAV integrants in mouse muscle. In the first approach, we were unable to recover host cell-vector DNA junctions from a lambda phage library generated using transduced mouse muscle DNA that contained a high vector copy number. Following this result, we devised a PCR assay based on the principle that integrated rAAV vector sequences could be amplified using primers specific for mouse interspersed repetitive sequences (B1 elements). Using this assay, we analyzed transduced mouse muscle DNA isolated from 6 to 57 weeks after injection and did not detect amplification above background levels. Based on the demonstrated sensitivity of the assay, these results suggested that >99.5% of vector DNA was not integrated. Additional analyses using a novel DNA exonuclease showed that the majority of the rAAV vector DNA in muscle persisted over time as transcriptionally active monomeric and concatameric episomes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12610125      PMCID: PMC149530          DOI: 10.1128/jvi.77.6.3495-3504.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

1.  Evolutionary history of B1 retroposons in the genus Mus.

Authors:  D H Kass; M E Raynor; T M Williams
Journal:  J Mol Evol       Date:  2000-09       Impact factor: 2.395

2.  Adeno-associated virus vector integration junctions.

Authors:  E A Rutledge; D W Russell
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector.

Authors:  X Xiao; J Li; R J Samulski
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

4.  Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus.

Authors:  J G Flannery; S Zolotukhin; M I Vaquero; M M LaVail; N Muzyczka; W W Hauswirth
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

5.  Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection.

Authors:  T Martin; S E Parker; R Hedstrom; T Le; S L Hoffman; J Norman; P Hobart; D Lew
Journal:  Hum Gene Ther       Date:  1999-03-20       Impact factor: 5.695

6.  Recombinant adeno-associated virus for muscle directed gene therapy.

Authors:  K J Fisher; K Jooss; J Alston; Y Yang; S E Haecker; K High; R Pathak; S E Raper; J M Wilson
Journal:  Nat Med       Date:  1997-03       Impact factor: 53.440

7.  Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors.

Authors:  S Song; J Embury; P J Laipis; K I Berns; J M Crawford; T R Flotte
Journal:  Gene Ther       Date:  2001-09       Impact factor: 5.250

8.  Structure of adeno-associated virus vector DNA following transduction of the skeletal muscle.

Authors:  N Vincent-Lacaze; R O Snyder; R Gluzman; D Bohl; C Lagarde; O Danos
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

9.  Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells.

Authors:  P L Hermonat; N Muzyczka
Journal:  Proc Natl Acad Sci U S A       Date:  1984-10       Impact factor: 11.205

10.  Cell lines for the production of recombinant adeno-associated virus.

Authors:  K R Clark; F Voulgaropoulou; D M Fraley; P R Johnson
Journal:  Hum Gene Ther       Date:  1995-10       Impact factor: 5.695

View more
  96 in total

Review 1.  Gene therapy: light is finally in the tunnel.

Authors:  Huibi Cao; Robert S Molday; Jim Hu
Journal:  Protein Cell       Date:  2012-01-10       Impact factor: 14.870

2.  Use of Adeno-Associated and Herpes Simplex Viral Vectors for In Vivo Neuronal Expression in Mice.

Authors:  Rachel D Penrod; Audrey M Wells; William A Carlezon; Christopher W Cowan
Journal:  Curr Protoc Neurosci       Date:  2015-10-01

3.  Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques.

Authors:  Philip R Johnson; Bruce C Schnepp; Mary J Connell; Daniela Rohne; Suzanne Robinson; Georgia R Krivulka; Carol I Lord; Rebekah Zinn; David C Montefiori; Norman L Letvin; K Reed Clark
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  In search of proof-of-concept: gene therapy for glycogen storage disease type Ia.

Authors:  Dwight D Koeberl
Journal:  J Inherit Metab Dis       Date:  2012-02-07       Impact factor: 4.982

Review 5.  Cardiac gene therapy.

Authors:  Antoine H Chaanine; Jill Kalman; Roger J Hajjar
Journal:  Semin Thorac Cardiovasc Surg       Date:  2010

Review 6.  Cardiac gene therapy with SERCA2a: from bench to bedside.

Authors:  Judith K Gwathmey; Alexan I Yerevanian; Roger J Hajjar
Journal:  J Mol Cell Cardiol       Date:  2010-11-18       Impact factor: 5.000

Review 7.  Challenges for gene therapy for muscular dystrophy.

Authors:  Jerry R Mendell; K Reed Clark
Journal:  Curr Neurol Neurosci Rep       Date:  2006-01       Impact factor: 5.081

8.  Regulation of episomal gene expression by KRAB/KAP1-mediated histone modifications.

Authors:  Isabelle Barde; Elisa Laurenti; Sonia Verp; Anna Claire Groner; Christopher Towne; Viviane Padrun; Patrick Aebischer; Andreas Trumpp; Didier Trono
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

9.  AAV-Mediated TAZ Gene Replacement Restores Mitochondrial and Cardioskeletal Function in Barth Syndrome.

Authors:  Silveli Suzuki-Hatano; Madhurima Saha; Skylar A Rizzo; Rachael L Witko; Bennett J Gosiker; Manashwi Ramanathan; Meghan S Soustek; Michael D Jones; Peter B Kang; Barry J Byrne; W Todd Cade; Christina A Pacak
Journal:  Hum Gene Ther       Date:  2018-10-03       Impact factor: 5.695

10.  Correction of glycogenosis type 2 by muscle-specific lentiviral vector.

Authors:  Emmanuel Richard; Gaëlle Douillard-Guilloux; Lionel Batista; Catherine Caillaud
Journal:  In Vitro Cell Dev Biol Anim       Date:  2008-09-23       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.